Get the Stockscreener App
1.07
0.00%
0.00
After Hours:
1.09
0.02
+1.87%
Enlivex Therapeutics Ltd stock is traded at $1.07, with a volume of 213.79K.
It is up +0.00% in the last 24 hours and down -31.85% over the past month.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
See More
Previous Close:
$1.07
Open:
$1.05
24h Volume:
213.79K
Relative Volume:
0.42
Market Cap:
$25.31M
Revenue:
-
Net Income/Loss:
$-14.33M
P/E Ratio:
-1.6212
EPS:
-0.66
Net Cash Flow:
$-13.21M
1W Performance:
+0.94%
1M Performance:
-31.85%
6M Performance:
-10.83%
1Y Performance:
-32.70%
1-Day Range:
$1.05
$1.08
1-Week Range:
$1.00
$1.08
52-Week Range:
$0.8101
$2.10
Enlivex Therapeutics Ltd Stock (ENLV) Company Profile
Name
Enlivex Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Compare ENLV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENLV
Enlivex Therapeutics Ltd
|
1.07 | 24.22M | 0 | -14.33M | -13.21M | -0.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Enlivex Therapeutics Ltd Stock (ENLV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-21 | Reiterated | H.C. Wainwright | Buy |
Enlivex Therapeutics Ltd Stock (ENLV) Latest News
Applying Elliott Wave Theory to Enlivex Therapeutics Ltd.Weekly Trend Recap & Community Trade Idea Sharing Platform - Newser
What technical models suggest about Enlivex Therapeutics Ltd.’s comebackPortfolio Gains Summary & Safe Capital Growth Trade Ideas - Newser
Is Enlivex Therapeutics Ltd. stock entering bullish territory2025 Growth vs Value & Risk Managed Investment Entry Signals - Newser
What data driven models say about Enlivex Therapeutics Ltd.’s futureMarket Volume Summary & AI Driven Stock Movement Reports - Newser
Best data tools to analyze Enlivex Therapeutics Ltd. stockSwing Trade & Reliable Trade Execution Plans - Newser
Can momentum traders help lift Enlivex Therapeutics Ltd.Entry Point & Safe Entry Momentum Stock Tips - Newser
Is this a good reentry point in Enlivex Therapeutics Ltd.2025 Market Trends & Risk Adjusted Swing Trade Ideas - Newser
Price momentum metrics for Enlivex Therapeutics Ltd. explainedEarnings Risk Summary & Reliable Trade Execution Plans - Newser
ENLV Stock: D. Boral Capital Maintains Buy Rating and $13 PT | E - GuruFocus
When is the best time to exit Enlivex Therapeutics Ltd.Weekly Profit Analysis & Free High Accuracy Swing Entry Alerts - Newser
Can technical indicators confirm Enlivex Therapeutics Ltd.’s reversal2025 Market Sentiment & Weekly High Return Opportunities - Newser
Evaluating Enlivex Therapeutics Ltd. with trendline analysisPortfolio Performance Summary & Community Trade Idea Sharing - Newser
Custom watchlist performance reports with Enlivex Therapeutics Ltd.2025 Breakouts & Breakdowns & Reliable Momentum Entry Alerts - Newser
Enlivex Announces Positive Phase IIa Results for Allocetra™ in Knee Osteoarthritis - MSN
Momentum divergence signals in Enlivex Therapeutics Ltd. chartM&A Rumor & Safe Investment Capital Preservation Plans - Newser
What earnings revisions data tells us about Enlivex Therapeutics Ltd.July 2025 Short Interest & Growth Focused Investment Plans - Newser
Will breakout in Enlivex Therapeutics Ltd. lead to full recoveryJuly 2025 Movers & Daily Risk Controlled Trade Plans - Newser
Relative strength of Enlivex Therapeutics Ltd. in sector analysisAnalyst Upgrade & Safe Investment Capital Preservation Plans - Newser
Multi asset correlation models including Enlivex Therapeutics Ltd.July 2025 Spike Watch & Weekly Top Performers Watchlists - Newser
Will Enlivex Therapeutics Ltd. continue its uptrendMarket Activity Recap & Risk Controlled Stock Pick Alerts - Newser
How moving averages guide Enlivex Therapeutics Ltd. tradingEarnings Summary Report & Community Supported Trade Ideas - Newser
Applying Wyckoff theory to Enlivex Therapeutics Ltd. stock2025 AllTime Highs & Detailed Earnings Play Alerts - Newser
Enlivex Announces Promising Phase IIa Results for Allocetra in Knee Osteoarthritis - MSN
price momentum metrics for enlivex therapeutics ltd. explainedMarket Growth Summary & Real-Time Sentiment Analysis - Newser
Enlivex (ENLV) Reports Promising Phase IIa Results for Allocetra in Osteoarthritis - GuruFocus
Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results - SINA HONG KONG LIMITED
72% Pain Reduction: Enlivex's Allocetra Demonstrates Breakthrough Results in Knee Osteoarthritis Trial - Stock Titan
Why Enlivex Therapeutics Ltd. is moving todayWeekly Trade Recap & Real-Time Stock Movement Alerts - Newser
Will Enlivex Therapeutics Ltd. stock go up soon2025 Geopolitical Influence & Free Technical Pattern Based Buy Signals - Newser
Is it time to cut losses on Enlivex Therapeutics Ltd.2025 Year in Review & Daily Momentum Trading Reports - Newser
Will Enlivex Therapeutics Ltd. outperform the marketPrice Action & Reliable Price Breakout Signals - Newser
Measuring Enlivex Therapeutics Ltd.’s beta against major indicesPortfolio Gains Report & Technical Confirmation Trade Alerts - Newser
Enlivex Therapeutics Ltd. stock trendline breakdown2025 Momentum Check & Stock Portfolio Risk Management - Newser
Developing predictive dashboards with Enlivex Therapeutics Ltd. dataJuly 2025 Sector Moves & Weekly Chart Analysis and Trade Guides - Newser
Is Enlivex Therapeutics Ltd. stock bottoming outEarnings Trend Report & Trade Opportunity Analysis Reports - Newser
Using data filters to optimize entry into Enlivex Therapeutics Ltd.Market Volume Report & Entry Point Confirmation Signals - Newser
Enlivex Secures Israeli Patent for Osteoarthritis Treatment - TipRanks
Enlivex Therapeutics Ltd Stock (ENLV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):